<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-UJQ8Q51P/a9c83276-1627-4698-b68a-006b04a2d9e1/PDF"><dcterms:extent>828 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-UJQ8Q51P/2fdc104c-13f8-40bc-b4f6-4a123b188eaa/TEXT"><dcterms:extent>20 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-UJQ8Q51P"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2016</dcterms:issued><dc:creator>Boltežar, Lučka</dc:creator><dc:creator>Jezeršek Novaković, Barbara</dc:creator><dc:creator>Žagar, Ivana</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:50</dc:format><dc:format xml:lang="sl">str. 355-359, I</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:2058619</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-UJQ8Q51P</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">diferencialna diagnoza</dc:subject><dc:subject xml:lang="en">differential diagnosis</dc:subject><dc:subject xml:lang="en">granulomatosis</dc:subject><dc:subject xml:lang="sl">granulomatoza</dc:subject><dc:subject xml:lang="sl">neHodginov limfom</dc:subject><dc:subject xml:lang="en">nonHodgin lymphoma</dc:subject><dc:subject xml:lang="en">PET-CT</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Granulomatosis after autologous stem cell transplantation in nonHodgkin lymphoma| experience of single institution and a review of literature|</dc:title><dc:description xml:lang="sl">Sarcoidosis before and after treatment of malignancy is an important differential diagnosis that has to be distinguished from lymphoma. Patients and methods. Hodgkin lymphoma, diffuse large B-cell lymphoma and aggressive follicular lymphoma are being staged and treatment effect is evaluated with PET-CT. We report three cases of aggressive lymphoma after high dose therapy and autologous stem cell transplantation with positive lymph nodes on PET-CT, which were histologically diagnosed as sarcoidosis/granulomatosis. In the literature, we found that false positive lymph nodes were more common after allogeneic than after autologous transplantation. Conclusions. Post-treatment PET-CT positive lymph nodes should always be examined histologically prior to any further treatment decision to avoid unnecessary toxic procedures</dc:description><dc:description xml:lang="sl">Sarkoidoza pred in po zdravljenju raka je pomembna diferencialna diagnoza, ki jo je potrebno razlikovati od limfoma. Bolniki in metode. Za oceno razširjenosti bolezni in učinkovitosti zdravljenja v skladu z novimi priporočili pri Hodgkinovem limfomu, difuznem velikoceličnem B limfomu in agresivnem folikularnem limfomu uporabljamo PET-CT. V članku opisujemo tri primere suma na ponovitev agresivnega limfoma (metabolno aktivne bezgavke na PET-CT) po visokodoznem zdravljenju in avtologni presaditvi krvotvornih matičnih celic. Pri vseh treh bolnikih smo histološko diagnosticirali sarkoidozo/ granulomatozo. V literaturi smo zasledili, da so lažno pozitivne bezgavke pogostejše po alogenični kot pa po avtologni presaditvi matičnih celic. Zaključki. Na PET-CT ugotovljene metabolno aktivne bezgavke po zdravljenju limfoma je potrebno vedno histološko opredeliti pred kakršno koli odločitvijo o nadaljnjem zdravljenju. Tako se izognemo morebitnim nepotrebnim postopkom, ki imajo lahko hude neželene učinke</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-UJQ8Q51P"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-UJQ8Q51P" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-UJQ8Q51P/a9c83276-1627-4698-b68a-006b04a2d9e1/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-UJQ8Q51P/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-UJQ8Q51P" /></ore:Aggregation></rdf:RDF>